Idiopathic Pulmonary Fibrosis

SAN FRANCISCO — Treatment with an oral preferential phosphodiesterase 4B inhibitor prevented lung function decline among patients with idiopathic pulmonary fibrosis, regardless of background antifibrotic therapy use.

Immune responses to COVID-19 vaccinations may trigger acute exacerbations in idiopathic pulmonary fibrosis among susceptible patients, according to data published in the American Journal of Respiratory and Critical Care Medicine.

A novel artificial intelligence-based system successfully quantified lung lesions and airway volumes on CT imaging among patients with idiopathic pulmonary fibrosis, according to data published in Annals of the American Thoracic Society.

Patients with idiopathic pulmonary fibrosis have similar magnitudes of response and completion rates for pulmonary rehabilitation compared with patients with COPD, according to a real-world study published in Chest.

Regardless of disease severity and lung transplant eligibility, patients with idiopathic pulmonary fibrosis who have access to a lung transplant center and live in more affluent areas have a higher probability of undergoing lung transplant.

In the past decade, the incidence of idiopathic pulmonary fibrosis nearly tripled and prevalence more than doubled among U.S. veterans, according to an analysis published in the Annals of the American Thoracic Society.

The FDA has granted breakthrough designation to a novel investigational therapy, BI 1015550, for treatment of patients with idiopathic pulmonary fibrosis, according to a press release from Boehringer Ingelheim.

Heavy smoking, based on pack-years, in adults with progressive fibrosing interstitial lung disease was associated with increased risk for mortality, according to research published in Respiratory Medicine.

In a new study, concomitant medication burden was associated with antifibrotic medication intolerance in patients with idiopathic pulmonary fibrosis.

The Healio Editors compiled the most-read chronic cough news published in 2021.